Status:
UNKNOWN
Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease
Lead Sponsor:
University of Sao Paulo
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Vogt Koyanagi Harada Disease
Eligibility:
All Genders
10-70 years
Phase:
NA
Brief Summary
This prospective study will include patients with Vogt-Koyanagi-Harada disease from disease onset, treated with early systemic high-dose corticosteroid and immunosuppressive therapy. Clinical and subc...
Detailed Description
Vogt-Koyanagi-Harada disease (DVKH) is an autoimmune disorder, which is mainly a T CD4+ Th1 lymphocyte mediated aggression to melanocytes, in individuals with a genetic predisposition, in particular, ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- \- acute Vogt-Koyanagi-Harada disease
- Exclusion criteria:
- non collaborative patient
- minimum one-year follow-up
Exclusion
Key Trial Info
Start Date :
March 23 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03399175
Start Date
March 23 2015
End Date
February 1 2025
Last Update
May 19 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de Sao Paulo
São Paulo, São Paulo, Brazil, 05403-000